HR+ MBC

Review of precision therapeutics and emerging strategies in HR+ MBC

Michelle DeMeo, Senior Program Manager at Dana-Farber Cancer Institute, shared on X:

Congratulations to Maxwell Lloyd, Kevin Kalinsky, Aditya Bardia, Komal Jhaveri and Seth Wander for recently published review of precision therapeutics and emerging strategies in HR+ MBC (metastatic breast cancer) in Nature Reviews Clinical Oncology.

Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer

Authors: Maxwell Lloyd, Kevin Kalinsky, Aditya Bardia, Komal Jhaveri and Seth Wander.

Review of precision therapeutics and emerging strategies in HR+ MBC

Source: Michelle DeMeo/X